Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Illumina, Inc.
  6. News
  7. Summary
    ILMN   US4523271090

ILLUMINA, INC.

(ILMN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Illumina : to Announce Third Quarter 2020 Financial Results on Thursday, October 29, 2020

09/28/2020 | 07:02am EDT

Illumina, Inc. (NASDAQ:ILMN) today announced that it will issue results for the third quarter 2020 following the close of market on Thursday, October 29, 2020.

On the same day, at 2:00 pm Pacific Time (5:00 pm Eastern Time) Francis deSouza, President and Chief Executive Officer, and Sam Samad, Chief Financial Officer, will host a conference call with analysts, investors, and other interested parties to discuss financial and operating results.

Conference Call Details

The conference call will begin at 2:00 pm Pacific Time (5:00 pm Eastern Time) on Thursday, October 29, 2020. Interested parties may access the live teleconference through the Investor Info section of Illumina’s website under the “company” tab at www.illumina.com. Alternatively, individuals can access the call by dialing 1 (866) 211-4597 or 1 (647) 689-6853 outside North America, both with Conference ID 9488740. To ensure timely connection, please dial in at least ten minutes before the scheduled start of the call.

A replay of the conference call will be posted on Illumina’s website after the event and will be available for at least 30 days following.

About Illumina

Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as the global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture and other emerging segments. To learn more, visit www.illumina.com and connect with us on Twitter, Facebook, LinkedIn, Instagram, and YouTube.


© Business Wire 2020
All news about ILLUMINA, INC.
06/01ILLUMINA  : Evercore ISI Upgrades Illumina to In-Line From Underperform
MT
06/01ILLUMINA  : Supports Nationwide Program across Belgium to Assess Whole Genome Se..
BU
05/31ILLUMINA  : and Next Generation Genomic Partner to Launch VeriSeq™ NIPT So..
BU
05/28Illumina Battles U.S., European Antitrust Enforcers on Grail Deal -- Update
DJ
05/28Illumina Battles U.S., European Antitrust Enforcers on Grail Deal
DJ
05/28ILLUMINA, INC.  : Submission of Matters to a Vote of Security Holders (form 8-K)
AQ
05/27INSIDER TRENDS : Illumina Insider Gets Shares Award Sells Portion for Taxes
MT
05/27INSIDER TRENDS : Insider at Illumina Receives Shares Award Uses Portion to Pay T..
MT
05/27INSIDER TRENDS : Illumina Insider Receives Shares Award Uses Portion to Pay Taxe..
MT
05/27INSIDER TRENDS : Insider at Illumina Gets Stock Award Makes Tax Sale with Portio..
MT
More news
Financials (USD)
Sales 2021 4 154 M - -
Net income 2021 714 M - -
Net cash 2021 1 672 M - -
P/E ratio 2021 92,7x
Yield 2021 -
Capitalization 66 163 M 66 163 M -
EV / Sales 2021 15,5x
EV / Sales 2022 13,7x
Nbr of Employees 7 825
Free-Float 74,7%
Chart ILLUMINA, INC.
Duration : Period :
Illumina, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ILLUMINA, INC.
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 22
Average target price 414,21 $
Last Close Price 453,17 $
Spread / Highest target 14,7%
Spread / Average Target -8,60%
Spread / Lowest Target -33,8%
EPS Revisions
Managers and Directors
NameTitle
Francis A. deSouza President, Chief Executive Officer & Director
Sam A. Samad Chief Financial Officer & Senior Vice President
John Wendell Thompson Chairman
Phillip G. Febbo Chief Medical Officer
Alex Aravanis CTO, Head-Research & Product Development
Sector and Competitors
1st jan.Capitalization (M$)
ILLUMINA, INC.22.48%66 163
THERMO FISHER SCIENTIFIC-0.14%182 817
DANAHER CORPORATION11.20%176 194
INTUITIVE SURGICAL, INC.5.64%102 341
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.10.33%89 297
SIEMENS HEALTHINEERS AG15.08%65 684